Mandate

Vinge advises the Second Swedish National Pension Fund and the Sixth Swedish National Pension Fund and their portfolio company Norrporten AB (publ) in relation to an exit process

April 15, 2016

Vinge advises the Second Swedish National Pension Fund and the Sixth Swedish National Pension Fund and their portfolio company Norrporten AB (publ) in relation to the exit process entailing a sale of Norrporten to a private buyer or an IPO and listing of shares in Norrporten on Nasdaq Stockholm.

The exit process resulted in a sale of Norrporten to Castellum AB (publ), listed on Nasdaq Stockholm, at a price of SEK 14.0 billion, based on an issue price in Castellum’s issue in kind of SEK 133 per share and including a dividend of SEK 464 million. Castellum will at closing pay SEK 10.4 billion in cash and 23.41 million Castellum shares to the AP-funds. Prior to the sale, Norrporten had been approved for listing on Nasdaq Stockholm by Nasdaq Stockholm’s listing committee.
 
Norrporten is one of Sweden’s largest office property companies with centrally located properties in Swedish urban growth centres and in Copenhagen. As of 31 December 2015, Norrporten’s property portfolio across eleven geographical market areas comprised 120 properties with a total leasable area of more than 1,140,000 square metres and an aggregate property value of SEK 25.8 billion.
 
Vinge’s team primarily consisted of Charlotte Levin, Fredrik Sonander, Joakim Hagberg, Erik Claesson, Nils Fredrik Dehlin and Joel Wahlberg. Maria Schultzberg, Emilie Parland, Ulf Käll and Victor Ericsson assisted in tax related matters, Albert Wållgren and Linn Adelwald assisted in financing related matters, Anna Palmérus and Karin Wisénius in competition law related matters and Åsa Gotthardsson assisted in employment law related matters.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025